+

WO2003000232A3 - Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides - Google Patents

Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides Download PDF

Info

Publication number
WO2003000232A3
WO2003000232A3 PCT/IL2002/000507 IL0200507W WO03000232A3 WO 2003000232 A3 WO2003000232 A3 WO 2003000232A3 IL 0200507 W IL0200507 W IL 0200507W WO 03000232 A3 WO03000232 A3 WO 03000232A3
Authority
WO
WIPO (PCT)
Prior art keywords
odn
iss
liposomes
immunostimulator
oligodeoxynucleotides
Prior art date
Application number
PCT/IL2002/000507
Other languages
French (fr)
Other versions
WO2003000232A2 (en
Inventor
Yechezkel Barenholz
Eliezer Kedar
Yigal Louria-Hayon
Aviva Joseph
Eyal Raz
Kenji Takabayashi
Original Assignee
Yissum Res Dev Co
Univ California
Yechezkel Barenholz
Eliezer Kedar
Yigal Louria-Hayon
Aviva Joseph
Eyal Raz
Kenji Takabayashi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Univ California, Yechezkel Barenholz, Eliezer Kedar, Yigal Louria-Hayon, Aviva Joseph, Eyal Raz, Kenji Takabayashi filed Critical Yissum Res Dev Co
Priority to AU2002311617A priority Critical patent/AU2002311617A1/en
Publication of WO2003000232A2 publication Critical patent/WO2003000232A2/en
Publication of WO2003000232A3 publication Critical patent/WO2003000232A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention is based on the finding of a simple and fast method for an effective entrapment of active ISS-ODN in liposomes, with more than 60% loading). The method is based on drying a suspension of amphipathic material and then hydrating it with an aqueous solution containing the ISS-ODN thereby entrapping it in liposomes formed from the lipid. Thus, the present invention concerns an efficient method for loading, and retaining, ISS-ODN in liposomal vesicles.Animals treated with liposomal ISS-ODN of the invention are shown to demonstrate a slower tempo of disease development as compared to free ISS-ODN or to liposomes loaded with mutant ISS-ODN (lip M-ODN).
PCT/IL2002/000507 2001-06-25 2002-06-25 Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides WO2003000232A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002311617A AU2002311617A1 (en) 2001-06-25 2002-06-25 Method for preparation of vesicles loaded with immunostimulatory oligodeoxynucleotides

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30007201P 2001-06-25 2001-06-25
US60/300,072 2001-06-25
US33978501P 2001-12-17 2001-12-17
US60/339,785 2001-12-17

Publications (2)

Publication Number Publication Date
WO2003000232A2 WO2003000232A2 (en) 2003-01-03
WO2003000232A3 true WO2003000232A3 (en) 2004-02-26

Family

ID=26971572

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2002/000507 WO2003000232A2 (en) 2001-06-25 2002-06-25 Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides

Country Status (2)

Country Link
AU (1) AU2002311617A1 (en)
WO (1) WO2003000232A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7935675B1 (en) 1994-07-15 2011-05-03 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
JP2006512927A (en) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド 5 'CPG nucleic acids and methods of use thereof
EP1610763A2 (en) * 2003-03-31 2006-01-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Stable liposomes or micelles comprising a sphingolipid and a peg-lipopolymer
JP5107573B2 (en) 2003-04-25 2012-12-26 ザ ペン ステイト リサーチ ファウンデーション Systemic delivery methods and systems for growth-inhibiting lipid-derived bioactive compounds
WO2007049279A2 (en) * 2005-10-26 2007-05-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem A liposomal combination and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172007A2 (en) * 1984-08-10 1986-02-19 Syntex (U.S.A.) Inc. Stable liposomes with aqueous-soluble medicaments and methods for their preparation
GB2164624A (en) * 1984-09-21 1986-03-26 Shionogi & Co Process for preparing liposome compositions
WO1999022772A1 (en) * 1997-10-31 1999-05-14 Isis Pharmaceuticals, Inc. LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS FOR MODULATING ras GENE EXPRESSION
WO2000045849A2 (en) * 1999-02-05 2000-08-10 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0172007A2 (en) * 1984-08-10 1986-02-19 Syntex (U.S.A.) Inc. Stable liposomes with aqueous-soluble medicaments and methods for their preparation
GB2164624A (en) * 1984-09-21 1986-03-26 Shionogi & Co Process for preparing liposome compositions
WO1999022772A1 (en) * 1997-10-31 1999-05-14 Isis Pharmaceuticals, Inc. LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS FOR MODULATING ras GENE EXPRESSION
WO2000045849A2 (en) * 1999-02-05 2000-08-10 Genzyme Corporation Use of cationic lipids to generate anti-tumor immunity
WO2001015726A2 (en) * 1999-08-27 2001-03-08 Inex Pharmaceuticals Corp. Compositions for stimulating cytokine secretion and inducing an immune response

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
GURSEL I ET AL: "Sterically stabilized cationic liposomes improve the uptake and immunostimulatory activity of CpG oligonucleotides.", JOURNAL OF IMMUNOLOGY, vol. 167, no. 6, 15 September 2001 (2001-09-15), pages 3324 - 3328, XP002228991, ISSN: 0022-1767 *
GÜRSEL M ET AL: "Immunoadjuvant action of plasmid DNA in liposomes.", VACCINE, vol. 17, no. 11-12, March 1999 (1999-03-01), pages 1376 - 1383, XP004158265, ISSN: 0264-410X *
LI WM ET AL: "Enhanced immune response to T-independent antigen by using CpG oligodeoxynucleotides encapsulated in liposomes.", VACCINE, vol. 20, no. 1-2, 12 October 2001 (2001-10-12), pages 148 - 157, XP004305127, ISSN: 0264-410X *
LUDEWIG B ET AL: "In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and anti-tumour immunity.", VACCINE, vol. 19, no. 1, 15 August 2000 (2000-08-15), pages 23 - 32, XP004228807, ISSN: 0264-410X *
MCCLUSKIE MJ ET AL.: "The potential of CpG oligodeoxynucleotides as mucosal adjuvants", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 21, no. 1-3, 2001, ISSN: 1040-8401, pages 103 - 120, XP008012997 *
MUI B ET AL: "Immune stimulation by a CpG-containing oligodeoxynucleotide is enhanced when encapsulated and delivered in lipid particles.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 298, no. 3, September 2001 (2001-09-01), pages 1185 - 1192, XP002228992, ISSN: 0022-3565 *
SONEHARA K ET AL: "Hexamer palindromic oligonucleotides with 5'-CG-3' motif(s) induce production of interferon.", JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, vol. 16, no. 10, 1996, pages 799 - 803, XP000863569, ISSN: 1079-9907 *

Also Published As

Publication number Publication date
WO2003000232A2 (en) 2003-01-03
AU2002311617A1 (en) 2003-01-08

Similar Documents

Publication Publication Date Title
WO2003000227A3 (en) A method for preparation of vesicles loaded with biological material and different uses thereof
DE3873528D1 (en) NYSTATIN CONTAINING LIPOSOME.
CA2252055A1 (en) Fusogenic liposomes
EP2292771A3 (en) Sense mRNA therapy
IS4675A (en) Micrograms for use as carriers for the administration of active substances
IL134703A (en) Process for controlling the loading of a biologically active agent into a liposome
AR001015A1 (en) A PROCEDURE FOR PREPARING A 1,3-PROPANODIOL BASED POLYESTER
ES2088160T3 (en) CHEMICAL FORMULATION AND PROCESS.
CA2305704A1 (en) Peptide/lipid complex formation by co-lyophilization
ATE172636T1 (en) LIPOSOMAL DELIVERY SYSTEM FOR BIOLOGICALLY ACTIVE SUBSTANCES
EP1025842A4 (en) Capsular preparation containing unsaturated fatty acid or derivative thereof and process for producing the same
ES2088385T3 (en) LIPOSOME FORMULATIONS WITH A HIGH ANTINEOPLASTIC AGENT / LIPID AGENT.
ZA9811948B (en) Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom.
WO1997030024A3 (en) Lipids and their use, for example, in liposomes
HUP9903334A2 (en) Method of producing morphologically uniform microcapsules and microcapsules produced by this method
BG103738A (en) Pharmaceutical composition containing freeze-dry liposomes including hard-soluble active substance in water, and method for its preparation
WO2001080840A3 (en) Cytotoxic agents comprising single-stranded and/or looped dna
ATE193830T1 (en) PREPARATIONS CONTAINING LEFLUNOMIDE
WO2003000232A3 (en) Method for preparation of vesicles loaded with immunostimulator y oligodeoxynucleotides
WO2003000233A3 (en) Delivery of small hydrophilic molecules packaged into lipid vesicles
DE60028152D1 (en) Solid, stable and concentrated biologically digestible complex of orthosilicic acid and process for its preparation
MXPA02005165A (en) COMMINUTED FORM OF (S) 2 ETHOXY 3 [4 (2 lcub;4 METHANESULFONYLOXYPHENYLrcub; ETHOXY) PHENYL] PROPANOIC ACID.
ATE459340T1 (en) TARGETED LIPOSOMES FOR GENE ADMINISTRATION
AU8243198A (en) Remedies for solid tumor containing wilms' tumor gene (wt1) expression inhibitors
EP0800822A3 (en) Method for preparing closed vesicles by rehydration of dehydrated vesicles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载